Gene · 9760
Papers2,030
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
461 to 480 of 2,030
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors. | Front Immunol | 2023 | 37435085 | PubTator, text mining | PubMed |
| Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade. | Oncogenesis | 2023 | 37433793 | PubTator, text mining | PubMed |
| RNA polymerase II dynamics shape enhancer-promoter interactions. | Nat Genet | 2023 | 37430091 | PubTator, text mining | PubMed |
| Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies. | Cancer Immunol Res | 2023 | 37429007 | PubTator, text mining | PubMed |
| Immunosurveillance shapes the emergence of neo-epitope landscapes of sarcomas, revealing prime targets for immunotherapy. | JCI Insight | 2023 | 37427594 | PubTator, text mining | PubMed |
| The diverse effects of transforming growth factor-β and SMAD signaling pathways during the CTL response. | Front Immunol | 2023 | 37426662 | PubTator, text mining | PubMed |
| SARS-CoV-2 Covid-19 Infection During Pregnancy and Differential DNA Methylation in Human Cord Blood Cells From Term Neonates. | Epigenet Insights | 2023 | 37425024 | PubTator, text mining | PubMed |
| Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity. | Front Cell Infect Microbiol | 2023 | 37424786 | PubTator, text mining | PubMed |
| Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. | J Transl Med | 2023 | 37420216 | PubTator, text mining | PubMed |
| IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation. | Front Immunol | 2023 | 37409128 | PubTator, text mining | PubMed |
| Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. | Nat Med | 2023 | 37407840 | PubTator, text mining | PubMed |
| Study on the mechanism of action of colchicine in the treatment of coronary artery disease based on network pharmacology and molecular docking technology. | Front Pharmacol | 2023 | 37405052 | PubTator, text mining | PubMed |
| Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. | J Immunother Cancer | 2023 | 37399356 | PubTator, text mining | PubMed |
| Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade. | Front Immunol | 2023 | 37398674 | PubTator, text mining | PubMed |
| TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation. | Immunity | 2023 | 37392737 | PubTator, text mining | PubMed |
| Single-cell profiling reveals age-associated immunity in atherosclerosis. | Cardiovasc Res | 2023 | 37390467 | PubTator, text mining | PubMed |
| Proteomics of immune cells from liver tumors reveals immunotherapy targets. | Cell Genom | 2023 | 37388918 | PubTator, text mining | PubMed |
| T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets. | Front Immunol | 2023 | 37388738 | PubTator, text mining | PubMed |
| T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures. | Essays Biochem | 2023 | 37386922 | PubTator, text mining | PubMed |
| A complementary low-Schottky-barrier S/D-based nanoscale dopingless bidirectional reconfigurable field effect transistor with an improved forward current. | Discov Nano | 2023 | 37382762 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9760/papers?page=24